Hypoxia Inducible Factor (HIF) Inhibitors
| Cat. No. | Product Name / Activity |
|---|---|
| 5953 | Adaptaquin |
| HIF-prolyl hydroxylase-2 (PHD2) inhibitor; antioxidant | |
| 5582 | TAT-cyclo-CLLFVY |
| Selective HIF-1 dimerization inhibitor | |
| 4408 | DMOG |
| Inhibitor of hypoxia-inducible factor α (HIF-α) prolyl hydroxylase (HIF-PH) | |
| 5520 | Echinomycin |
| Highly potent and selective HIF-1α inhibitor | |
| 6653 | FM19G11 |
| HIF α-subunit inhibitor | |
| 5655 | GN 44028 |
| Potent HIF-1α inhibitor | |
| 4451 | IOX 2 |
| Potent, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor | |
| 4324 | KC7F2 |
| HIF-1α inhibitor; down-regulates HIF-1α protein synthesis | |
| 6322 | LW 6 |
| HIF-1α inhibitor; inhibits cellular accumulation of HIF-1α; also malate dehydrogenase-2 inhibitor | |
| 2954 | PX 12 |
| Thioredoxin-1 inhibitor; attenuates expression of HIF-1α | |
| 5243 | TC-S 7009 |
| High affinity and selective HIF-2α inhibitor | |
| 6156 | VH 298 |
| High-affinity inhibitor of VHL; blocks interaction of VHL and HIF-α |
Cancer Research Product Guide
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyRequest PDFAngiogenesis in Cancer Life Science Poster
Taken from the Cancer Product Guide Edition 3
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDF